Having trouble accessing articles? Reset your cache.

PX-866: Phase II data

Oncothyreon disclosed in its 1Q13 earnings that data from a cohort of 95 patients with non-small cell lung cancer (NSCLC) receiving second

Read the full 229 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE